SecBot SecBot
6-K ·Filed Jul 2, 2026

HCM

HUTCHMED (China) Ltd
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago SEC0001648257-26-000047
Notable filing: 6-K
Actionable Insight ▲ Bullish

This label expansion adds a new revenue driver for HUTCHMED's partnered asset; watch for NRDL inclusion for this indication to accelerate volume. The existing commercial infrastructure via AstraZeneca and prior NRDL listing for lung cancer de-risks launch execution. Monitor upcoming quarterly results for initial prescription trends.

DirectionBullish
Confidencehigh
Horizonweeks

Drug in focus

HCM drug pipeline →

ORPATHYS

◆ Mixed Named in this 6-K
Impact
Phase
Approved in China (3 indications); global Phase 3 readout pending
Time to market
Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
Next catalyst
None dated

What to watchWatch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$11.44
T+0 close · Jul 2, 2026 · via day close
Latest settled
+21.50%
T+60 · $13.90
Vs SPY
+18.50%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 2 $11.44entry
  2. T+1 · 4mo ago +1.84%α +0.96% · $11.65
  3. T+5 · 4mo ago −4.02%α −4.95% · $10.98
  4. T+20 · 4mo ago −5.86%α −5.44% · $10.77
  5. T+60 · 7w ago +21.50%α +18.50% · $13.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HUTCHMED (HCM) announces conditional NMPA approval in China for ORPATHYS (savolitinib) to treat MET-amplified advanced gastric or gastroesophageal junction adenocarcinoma in patients who have failed at least two prior systemic treatments. This is the third approved indication for ORPATHYS in China, supported by a pivotal Phase II study showing a 32.3% objective response rate, and the drug is already on the National Reimbursement Drug List for its prior lung cancer indication, providing a clear commercial path alongside partner AstraZeneca.

Key Facts

  • ORPATHYS (savolitinib) received conditional NMPA approval for MET-amplified advanced GC/GEJ adenocarcinoma after >=2 prior systemic treatments
  • Approval supported by Phase II study (NCT04923932): IRC-assessed ORR 32.3% (95%CI: 21.2%-45.1%), DCR 63.1%, median DoR 9.7 months, median PFS 4.0 months
  • Estimated annual incidence of MET-amplified gastric cancer in China is ~18,000 patients (~4-6% of all gastric cancer cases)
  • This is the third approved indication for ORPATHYS in China; it is already on the NRDL (since March 2023) for prior lung cancer indication
  • Drug is jointly developed with AstraZeneca, which commercializes it in China

Financial Impact

Expands the addressable patient population for ORPATHYS by adding ~18,000 incident MET-amplified GC/GEJ patients per year in China. Revenue contribution will depend on NRDL pricing, market penetration, and duration of therapy (median DoR 9.7 months). As the first selective MET inhibitor approved for this indication, near-term revenue upside is clear but not yet quantifiable from the filing alone.

revenue

Risk Factors

  • Conditional approval may require confirmatory trial data; failure to meet post-marketing requirements could lead to label restriction
  • MET amplification prevalence is only ~4-6% of gastric cancer, limiting absolute patient numbers
  • Pricing and NRDL negotiation for this specific indication are unknown; reimbursement terms could constrain margins

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001648257-26-000047
Document: hcm-20260702x6k.htm0001648257-26-000047
Document: 0001648257-26-000047-index-headers.html0001648257-26-000047
Document: 0001648257-26-000047-index.html0001648257-26-000047
Document: 0001648257-26-000047.txt0001648257-26-000047

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026